Summary:
- The CDC's approval of Pfizer's RSV vaccine for adults aged 50-59 strengthens Pfizer's market position.
- Analysts predict moderate upside potential for Pfizer Inc (PFE, Financial) based on current stock evaluations.
- GuruFocus estimates indicate a potential value increase for Pfizer over the next year.
CDC's Approval: A Boost for Pfizer and GSK
The Centers for Disease Control and Prevention (CDC) has made a significant move by approving RSV vaccines for adults aged 50-59. This decision notably benefits pharmaceutical giants Pfizer (NYSE: PFE) and GlaxoSmithKline (GSK). Pfizer's vaccine, Abrysvo, is already approved for this particular age group, setting it apart from Moderna (NASDAQ: MRNA), which is still awaiting approval from the FDA for its RSV vaccine intended for adults aged 18-59. This strategic advantage could potentially enhance Pfizer's market presence and revenue stream in the coming years.
Wall Street Analysts' Forecast
According to forecasts from 21 analysts, Pfizer Inc (PFE, Financial) shows promising growth prospects with an average one-year price target of $28.57. Estimates range between a high of $41.49 and a low of $23.00. Compared to the current price of $25.28, the average target suggests a potential upside of 13.02%. For more in-depth estimate data, visit the Pfizer Inc (PFE) Forecast page.
The brokerage consensus from 25 firms offers Pfizer Inc (PFE, Financial) an average recommendation of 2.6, equating to a "Hold" status on a scale where 1 signifies a Strong Buy and 5 indicates a Sell. This consensus reflects a generally cautious yet optimistic outlook by analysts on Pfizer's stock performance.
Pfizer's Estimated GF Value
GuruFocus's evaluation shows that Pfizer Inc (PFE, Financial) has an estimated GF Value of $27.28 in one year, revealing an anticipated upside of 7.91% from its current trading price of $25.28. The GF Value represents GuruFocus's assessment of the fair value at which the stock should ideally trade. It is determined by historical trading multiples, past business growth, and projected business performance. For further details, explore the Pfizer Inc (PFE) Summary page.
